

| | |
|--------------|--|
| Institution | Oklahoma State University - Center for Health Sciences |
| Meeting Date | Thursday, June 18 2025 |
| Meeting Time | 10:00 AM |
| Meeting Type | In-person Meeting |

| IBC Members Present | Name | Role | Attendance |
|---------------------|--|---|--------------------------------------|
| | Dr. Gerwald Koehler | Committee Chair | Present |
| | Dr. I-Hsiu (George) Huang | Scientific Member | Present |
| | Dr. Sue Katz Amburn | Non-affiliated Member | Present |
| | Dr. Crystal (Niki) Johnson | Scientific Member | Present |
| | William (BJ) Reddig | Lab representative | Present |
| | Dr. Fang (Fiona) Liu | Non-affiliated member | Present |
| | Dr. David Wallace | Animal Expert | Present |
| | Dr. Vikram Gujar | Alternate Member - Affiliated Scientist | Present, non-voting for this meeting |
| Quorum | Quorum is met. The IBC has seven (7) voting members present, and four (4) voting members are required to conduct business. | | |

| Others in Attendance | Name | Affiliation | Title |
|----------------------|-------------------|--|--|
| | Kadin Falkenstein | Oklahoma State University - Center for Health Sciences | Research Compliance Coordinator, Biosafety Officer |

| | | | |
|---|---|------------------------------|-------------------------------------|
| Call to Order | The IBC Chair called this meeting to order at 10:00am. | | |
| Conflicts of Interest | The IBC Chair asked all members present to identify any conflicts of interest with the materials that are to be reviewed. No Conflicts of Interest were noted for this meeting. | | |
| Discussion of previous minutes | BJ Reddig made the motion to approve as written, and Dr. Katz Amburn seconded. No discussion was had regarding the minutes. | | |
| Review and Approval of previous meeting minutes | Date of previous meeting Thursday, April 17 2025 | Motion Approve as Written | Votes; for/against/abstain 7/0/0 |

| | | |
|--------------------------|---|--|
| Review of Prior Business | Business | Review and Discussion |
| | Report of pending/outstanding protocol(s) | Kadin Falkensten discussed the pending and outstanding protocol documents. At this meeting, there are no protocols outstanding for review and three (3) protocols that were previously reviewed and are pending revisions from their primary investigators. No action is required from the IBC at this time. |

| New IBC Registrations and Amendments for Review | | |
|---|--|--------------|
| Review of IBC-00001237 | | |
| PI Name(s) | Dr. Subhas Das | |
| Registration Title/Number | Epigenetic Regulation in Pleural Inflammation | IBC-00001237 |
| Project Overview | <p>Through previous studies, the Das lab has found that Glutaminase 1 (GLS1) is a novel biomarker for colon inflammation. To confirm whether GLS1 is a specific marker for colon inflammation, or it is pan-inflammatory marker for other inflammation as well, we wanted to investigate other inflammatory models. For this study a carrageenan-induced pleurisy model leading to pleural inflammation will be studied. This study will involve the use of A549 Lung Carcinoma cells, Lewis Lung carcinoma cells, and tissues harvested from Sprague-Dawley rats post-mortem. A549 and Lewis lung carcinomas are from established, ATCC-purchased cell lines and do not have any characteristics of note. No nucleic acid sequences, aside from those found naturally in the listed cell lines and rats, will be used in this experiment. No host/vector systems will be used in this project, and no modifications will be made to any nucleic acid sequences. This project involves the experimental manipulations of cell culture and working with animals and therefore will have a proposed Biosafety Level of BL-2. This project seeks to establish DNA methylation of GLS gene in acute pleural inflammation, determine if blocking DNA methylation will resolve the pleural inflammation in WT and GLS+/- rats, identify aberrant DNA methylation of GLS during malignant pleural inflammation using tumor cells, and understand the role of ER stress and Unfolded Protein Response (UPR) during pleural inflammation and whether using UPR inhibitors alleviate pleural inhibition.</p> | |
| NIH Guidelines Section | App. C-VII, III-D-4-b | |
| Risk Assessment and | Risk Assessment: Use of animals with biohazards (Human/NHP Cell lines); Use of sharps (Glassware) | |

| | | | |
|---|---|---|----------|
| Discussion | Discussion: Use of animals in conjunction with biohazards can lead to accidental exposure; all personnel will take proper animal handling training, and incidents will be reported to IBC and IACUC immediately. Use of sharps, specifically glassware, noted as the chance of accidentally generating sharps via broken glassware is possible; care and attention should be taken in the lab to prevent accidents. | | |
| Training | All personnel listed on this application have completed the minimum required lab safety training courses, including Lab Chemical safety, Bloodborne Pathogens training, and Laboratory Biosafety training. Additionally, all personnel have documented in-lab training for specific procedures that are carried out in each individual lab. | | |
| Additional Training | The IBC recommends that all personnel take the online training courses for Working with Rats and the Animal Researchers training courses. | | |
| Occupational Health Representative Review (if applicable) | All personnel who will be working with animals are to be enrolled in the OLAW-compliant occupational health program prior to beginning work with the animals. | | |
| Biosafety Level Assignment | Biosafety Level: | 2 | |
| | Additional Discussion or notes: | Care should be taken when handling animals to prevent accidental exposure | |
| IBC Vote | Motion: | Defer vote, more information needed from PI | |
| | | 1st: N/A | 2nd: N/A |
| | Votes, for/against/abstain/recused: | None | |
| | Notes: | Too many revisions required of the PI, the IBC will request that the PI make the required revisions and re-submit the protocol for IBC review at the next applicable meeting. | |

| New Business | Topic | Discussion |
|--------------|-------------------|---|
| | IBC Bylaws Update | Dr. Koehler discussed the need to update the IBC's bylaws to review the process for renewing or re-training external IBC members, as well as to generally review the bylaws to ensure that they are still appropriate with new regulations. |

| | | |
|---------------------------|----------------------|--|
| Additional/Other Business | NIH/OSP Requirements | Kadin Falkensten noted that the NIH/OSP changes to the website and regulations are now in effect. Kadin showed the members the changes to the website, and explained the current plans for how we will go about publishing the minutes on the website. |
|---------------------------|----------------------|--|

| | |
|-------------------------------|---|
| Review of Incidents | Nothing to report. |
| Inspections/Ongoing Oversight | Nothing to report. |
| IBC Training | No IBC training was conducted at this meeting. |
| Public Comments | There were no public comments. |
| Adjournment | The IBC Chair moved to adjourn the meeting at 10:45am. The next IBC meeting is scheduled for Thursday, July 17 2025. |